Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.
about
In Vivo Performance and Properties of Tamoxifen Metabolites for CreERT2 ControlPharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.Quantitative Systems Pharmacology: A Framework for Context.Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels.Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
P2860
Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Concomitant use of tamoxifen a ...... ased pharmacokinetic modeling.
@ast
Concomitant use of tamoxifen a ...... ased pharmacokinetic modeling.
@en
type
label
Concomitant use of tamoxifen a ...... ased pharmacokinetic modeling.
@ast
Concomitant use of tamoxifen a ...... ased pharmacokinetic modeling.
@en
prefLabel
Concomitant use of tamoxifen a ...... ased pharmacokinetic modeling.
@ast
Concomitant use of tamoxifen a ...... ased pharmacokinetic modeling.
@en
P2093
P2860
P356
P1433
P1476
Concomitant use of tamoxifen a ...... ased pharmacokinetic modeling.
@en
P2093
Georg Hempel
Kristin Dickschen
Matthias Schwab
Stefan Willmann
Thomas Eissing
Thomas Mürdter
P2860
P2888
P356
10.1186/2193-1801-3-285
P577
2014-06-05T00:00:00Z
P5875
P6179
1008915655